Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Indian biotechnology firm Biocon has reinforced its ambitions to bring to market an orally delivered insulin and said it stays firmly on track as it found several "unique and positive" takeaways from its recently concluded Phase III clinical trials in India

You may also be interested in...



BMS, Biocon Team Up To Rekindle Oral Insulin Hopes

After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”

BMS, Biocon Team Up To Rekindle Oral Insulin Hopes

After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”

Biocon Completes Phase I Trial For Lantus Biosimilar, As Speculation Builds On Deal For Oral Insulin

A steadily developing pipeline – including a biosimilar of Sanofi’s blockbuster diabetes therapy Lantus – is starting to bear fruit. Meanwhile, speculation is building that Biocon is close to partnering its oral insulin IN-105, with Bristol-Myers Squibb as a rumored suitor.

Related Content

UsernamePublicRestriction

Register

SC076222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel